Position in CELC
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$53,816,109
New position
Shares Held
514,396
first reported quarter
Ownership
1.05%
of shares outstanding
% of Portfolio
0.15%
of 13F equity value
Holder Rank
#26
of 273 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 95%
Shared 0%
None 5%
Position in Biotechnology
Healthcare · as of Jun 30, 2026FULLER & THALER ASSET MANAGEMENT, INC. holds $1,207,612,518 across 7 Biotechnology names. CELC ranks #6 (4.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
|
8,929,389 | $485,848,055 | |
| 2 | JAZZ |
Jazz Pharmaceuticals plc
|
1,638,544 | $394,839,947 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
1,491,004 | $116,700,883 | |
| 4 | PTCT |
Ptc Therapeutics, Inc.
|
1,156,819 | $94,361,725 | |
| 5 | CORT |
Corcept Therapeutics Inc
|
710,106 | $61,743,716 | |
| 6 | CELC |
Celcuity Inc.
This page
|
514,396 | $53,816,109 | |
| 7 | VNDA |
Vanda Pharmaceuticals Inc.
|
49,360 | $302,083 |
All Filings in CELC
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $53,816,109 | 514,396 | Shares | Sole | 2026-08-12 | |
| No filing history on record for this holder in this stock. | ||||||